Journal of opioid management · 2026
Buprenorphine microinductions: Investigating the ideal initial dose based on oral morphine equivalent requirements for stabilizing withdrawal symptoms.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Coldren Temple C, Costello Jennifer L, Guglielmo Kimberly A, Wood Katlyn C
Аннотация
OBJECTIVE: To determine if a relationship exists between oral morphine equivalent (OME) requirements to stabilize acute opioid withdrawal symptoms and the initial buprenorphine dose in patients who successfully complete a buprenorphine microinduction, defined as discharge on buprenorphine.
DESIGN: Retrospective chart review.
SETTING: Single-center community teaching hospital in Lancaster, Pennsylvania.
PATIENTS AND PARTICIPANTS: Included adult patients admitted to Penn Medicine Lancaster General Hospital from February 1, 2022, to February 1, 2025, with opioid use disorder, who attempted a buprenorphine microinduction. A microinduction was defined as an initial sublingual buprenorphine dose less than 2 mg or a buccal dose less than 900 mcg. Patients were excluded if they were on buprenorphine prior to admission. Thirty patients met criteria for inclusion.
MAIN OUTCOME MEASURE: To determine if the 24-hour OME received on the day of buprenorphine initiation (stabilizing OME) is predictive of the starting buprenorphine dose among patients who had a successful microinduction.
RESULTS: Of the 30 patients, 25 (83.3 percent) successfully completed a microinduction. Among these 25 patients, there was no statistically significant association found between the initial buprenorphine dose and either the stabilizing OME or the self-reported quantity of illicit opioid use. Similarly, microinduction length was not significantly associated with either variable.
CONCLUSIONS: Findings support an individualized approach to buprenorphine microinductions, as no statistically significant associations were found between the initial buprenorphine dose and stabilizing OME requirements.
DESIGN: Retrospective chart review.
SETTING: Single-center community teaching hospital in Lancaster, Pennsylvania.
PATIENTS AND PARTICIPANTS: Included adult patients admitted to Penn Medicine Lancaster General Hospital from February 1, 2022, to February 1, 2025, with opioid use disorder, who attempted a buprenorphine microinduction. A microinduction was defined as an initial sublingual buprenorphine dose less than 2 mg or a buccal dose less than 900 mcg. Patients were excluded if they were on buprenorphine prior to admission. Thirty patients met criteria for inclusion.
MAIN OUTCOME MEASURE: To determine if the 24-hour OME received on the day of buprenorphine initiation (stabilizing OME) is predictive of the starting buprenorphine dose among patients who had a successful microinduction.
RESULTS: Of the 30 patients, 25 (83.3 percent) successfully completed a microinduction. Among these 25 patients, there was no statistically significant association found between the initial buprenorphine dose and either the stabilizing OME or the self-reported quantity of illicit opioid use. Similarly, microinduction length was not significantly associated with either variable.
CONCLUSIONS: Findings support an individualized approach to buprenorphine microinductions, as no statistically significant associations were found between the initial buprenorphine dose and stabilizing OME requirements.